Company intelligence / Profile preview

Wavelength Pharmaceuticals

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

Wavelength Pharmaceuticals develops and manufactures active pharmaceutical ingredients (APIs) at commercial scale. They have more than 30 years of regulatory track record with global authorities and offer full-spectrum API CDMO services from pre-clinical to commercial scale. Their expertise includes complex chemistry, process development/scale-up, enzymatic reactions, crystalline forms/particle design, spray drying and bioavailability-enhancing solutions.

Therapeutic areas: DermatologyImmunologyNeurology
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Drug pipeline

3 assets

cannabidiol

Commercial

Indications: Epilepsy

2 more assets in the full pipeline.

Request access →

Partnerships

On Demand PharmaceuticalsBIRD Foundation

Beyond the preview

Go deeper on Wavelength Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wavelength Pharmaceuticals.

Explore the full profile